Home/Pipeline/Alzheimer's Drug

Alzheimer's Drug

Alzheimer’s disease

DevelopmentActive

Key Facts

Indication

Alzheimer’s disease

Phase

Development

Status

Active

Company

Dawah Pharmaceuticals

About Dawah Pharmaceuticals

Dawah Pharmaceuticals is a commercial-stage generic drug company employing a capital-light, partnership-driven model to bring essential medicines to market. Its strategy centers on identifying and filling supply gaps for sterile injectable and ophthalmic products by collaborating with top-tier international CMOs, primarily for U.S. market entry. Backed by leadership with decades of healthcare experience, the company is building a diverse pipeline targeting therapeutic areas like critical care, oncology, and CNS disorders, with several product launches projected from 2026 onward. Dawah's approach combines U.S. regulatory expertise with cost-effective global manufacturing to improve drug access and affordability.

View full company profile

Therapeutic Areas

Critical Care Oncology Mental Health Infectious Disease Ophthalmology Cardiovascular Metabolic Disorders Neurology Pain Management

Other Alzheimer’s disease Drugs

Drug	Company	Phase	Status
RASTRUM™ 3D Alzheimer’s Disease Model	Inventia Life Science	Pre‑clinical	Active
SPC-14	Silo Pharma	Preclinical	Research
Masitinib	AB Science	Phase 3	Active
Vaxine Alzheimer’s Disease Vaccine	Vaxine	Preclinical	Active
Leronlimab	CytoDyn	Phase 1	Phase in progress
Sovateltide	Pharmazz	Preclinical	Active
Alzheimer’s Clinical Trials	Boston Clinical Trials	Not Specified (Typically Phase 2-3)	Active
ONO-2020	Deciphera Pharmaceuticals	Phase 2	Active
Blarcamesine (ANAVEX®2-73)	Anavex Life Sciences	Phase 2b/3	Ongoing